Home › Funds › Parkman Healthcare Partners LLC › INBX
Parkman Healthcare Partners LLC position in INBX
INHIBRX BIOSCIENCES INC · Health Care
Parkman Healthcare Partners LLC reported holding 360,260 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$36.1M, representing 3.25% of its reported portfolio and ranking #6 among its reported holdings. Parkman Healthcare Partners LLC has disclosed INBX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's INBX position evolved
Parkman Healthcare Partners LLC first disclosed a stake in INBX in Q2 2026 at 256,950 shares (US$24.3M). The position peaked in Q3 2026 at 360,260 shares, worth US$36.1M. Across 2 filings, Parkman Healthcare Partners LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 360,260 shares valued at US$36.1M — an increase of 103,310 shares quarter over quarter.. Notable position changes include a 40% increase in Q3 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 256.95K | $24.35M | New |
| Q3 2026 | 360.26K | $36.05M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 40 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$123.0M), Sanofi (US$115.9M), Schonfeld Strategic Advisors LLC (US$66.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- PERCEPTIVE ADVISORS LLC 1.30M sh · $122.96M · Q2 2026
- Sanofi 1.16M sh · $115.89M · Q3 2026
- Schonfeld Strategic Advisors LLC 697.59K sh · $66.10M · Q2 2026
- Sofinnova Investments, Inc. 391.62K sh · $39.19M · Q3 2026
- PFM Health Sciences, LP 320.33K sh · $32.06M · Q3 2026
- First Turn Management, LLC 171.51K sh · $17.16M · Q3 2026
- Trails Edge Capital Partners, LP 170.00K sh · $17.01M · Q3 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held INBX?
Parkman Healthcare Partners LLC has disclosed INBX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Parkman Healthcare Partners LLC's current position in INBX?
As of Q3 2026, Parkman Healthcare Partners LLC holds 360.26K shares of INBX (INHIBRX BIOSCIENCES INC), valued at $36.05M, representing 3.25% of its reported portfolio and ranking #6.
Has Parkman Healthcare Partners LLC been buying or selling INBX?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in INBX. The position peaked in Q3 2026 at 360.26K shares.
Which other funds hold INBX?
Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, Schonfeld Strategic Advisors LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.